drugset / Trial / NCT00402103

An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure

NCT00402103

Phase 3 Completed 556 enrolled Novartis
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg / amlodipine 10 mg in patients with essential hypertension (Mean Sitting Diastolic Blood Pressure \[msDBP\] ≥ 90 mmHg and \< 110 mmHg).

Timeline

Start
2006-11
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg
Subject Amlodipine Other / unclassified 10 mg
Subject Hydrochlorothiazide Unknown 25 mg